My Genome Screen provides an AI-powered platform that accelerates rare disease diagnosis by efficiently interpreting genetic variants. Its system prioritizes disease-causing mutations from complex genomic data, enabling clinicians to identify genetic disorders faster and facilitate targeted treatments.
Funding
$30K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The diagnostic journey for rare diseases is often prolonged, with patients facing an average of five years and multiple physician consultations before receiving an accurate diagnosis. This delay hinders timely intervention and can negatively impact patient outcomes.
Solution
My Genome Screen offers an AI-powered platform designed to streamline genetic variant interpretation and accelerate rare disease diagnosis. The system leverages a sophisticated AI module, augmented by curated in-house models, to accurately prioritize disease-causing mutations from complex genomic data. This approach significantly reduces the time required for variant analysis, enabling clinicians to identify the root cause of genetic disorders more efficiently. By facilitating earlier and more precise genetic insights, the platform supports the implementation of targeted treatments and proactive preventive medicine strategies.
Target Audience
The primary users are clinical geneticists, molecular diagnosticians, and healthcare providers involved in rare disease diagnosis and genetic counseling.
Features
- AI-driven variant prioritization engine for complex genomic datasets.
- Integration of manually curated in-house models to enhance diagnostic accuracy.
- Accelerated identification of disease-causing mutations to shorten the diagnostic odyssey.
- Support for carrier screening to identify inherited disease risks prior to pregnancy.
- Facilitates early detection of genetic predispositions for improved treatment and preventive care.